Adiponectin and leptin expression in primary ductal breast cancer and in adjacent healthy epithelial and myoepithelial tissue

Jardé, Thierry; Caldefie-Chézet, Florence; Damez, Mireille; Mishellany, Florence; Perrone, Daniel; Penault‐Llorca, Frédérique; Guillot, Jean; Vasson, Marie‐Paule

doi:10.1111/j.1365-2559.2008.03121.x

Cited by 42 publications

(34 citation statements)

References 5 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interestingly, leptin mRNA expression in MCF-7 cells was dramatically higher (34.7-fold) than adiponectin mRNA expression. This finding is in accordance with our previous immunohistochemical study, where adiponectin-positive staining was noted in 15% of the 45 breast cancer tissues studied and leptin-positive staining was observed in 80% of the 45 breast cancer tissues (Jarde et al 2008b). These results suggest that leptin is much more abundant in the local breast cancer environment than adiponectin.…”

Section: Discussionsupporting

confidence: 82%

Involvement of adiponectin and leptin in breast cancer: clinical and in vitro studies

Jardé

Caldefie-Chézet

Goncalves-Mendès

et al. 2009

Endocrine-Related Cancer

Self Cite

135

121

View full text Add to dashboard Cite

Obesity is a risk factor for breast cancer development. A recent hypothesis suggests that the adipokines, adiponectin and leptin, are involved in breast cancer development. This prompted us to investigate the role of adiponectin and leptin in mammary carcinogenesis. Adiponectin receptors (AdipoR1 and AdipoR2) and leptin receptor (Ob-Rt, representing all the isoforms of Ob-R) proteins were detected by immunohistochemistry in in situ ductal carcinoma, invasive ductal malignancy, and healthy adjacent tissue. In addition, mRNA expression of adiponectin, AdipoR1, AdipoR2, leptin, Ob-Rt, and Ob-Rl (the long isoform of Ob-R) was observed in MCF-7 breast cancer cells. Interestingly, leptin mRNA expression was 34.7-fold higher than adiponectin mRNA expression in the MCF-7 cell line. Moreover, adiponectin (10 mg/ml) tended to decrease the mRNA expression of leptin (K36%) and Ob-Rl (K28%) and significantly decreased Ob-Rt mRNA level (K26%). In contrast, leptin treatment (1 mg/ml) significantly decreased AdipoR1 mRNA (K23%). Adiponectin treatment (10 mg/ml) inhibited the proliferation of MCF-7 cells, whereas leptin (1 mg/ml) stimulated the growth of cancer cells. In addition, adiponectin inhibited leptin-induced cell proliferation (both 1 mg/ml). Using microarray analysis, we found that adiponectin reduced the mRNA levels of genes involved in cell cycle regulation (mitogen-activated protein kinase 3 and ATM), apoptosis (BAG1, BAG3, and TP53), and potential diagnosis/prognosis markers (ACADS, CYP19A1, DEGS1, and EVL), whereas leptin induced progesterone receptor mRNA expression.In conclusion, the current study indicates an interaction of leptin-and adiponectin-signaling pathways in MCF-7 cancer cells whose proliferation is stimulated by leptin and suppressed by adiponectin.

show abstract

Section: Discussionsupporting

confidence: 82%

Involvement of adiponectin and leptin in breast cancer: clinical and in vitro studies

Jardé

Caldefie-Chézet

Goncalves-Mendès

et al. 2009

Endocrine-Related Cancer

Self Cite

135

121

View full text Add to dashboard Cite

show abstract

“…In a recent study, Jarde et al [97] analyzed the immunohistochemical expression of adiponectin and leptin in 45 primary breast ductal cancers, 14 ductal carcinomas in situ, and 40 normal breast tissues located adjacent to breast cancer. They found adiponectin and leptin immunoreactivity in 75% and 80% of normal breast tissue samples, respectively.…”

Section: Studies On Breast Cancer Which Considered Both Leptin and Admentioning

confidence: 99%

Obesity and breast cancer: status of leptin and adiponectin in pathological processes

Großmann

Ray

Nkhata

et al. 2010

Cancer Metastasis Rev

161

108

View full text Add to dashboard Cite

It is well recognized that obesity increases the risk of various cancers, including breast malignancies in postmenopausal women. Furthermore, obesity may adversely affect tumor progression, metastasis, and overall prognosis in both pre- and postmenopausal women with breast cancer. However, the precise mechanism(s) through which obesity acts is/are still elusive and this relationship has been the subject of much investigation and speculation. Recently, adipose tissue and its associated cytokine-like proteins, adipokines, particularly leptin and adiponectin, have been investigated as mediators for the association of obesity with breast cancer. Higher circulating levels of leptin found in obese subjects could be a growth-enhancing factor as supported by in vitro and preclinical studies, whereas low adiponectin levels in obese women may be permissive for leptin's growth-promoting effects. These speculations are supported by in vitro studies which indicate that leptin promotes human breast cancer cell proliferation while adiponectin exhibits anti-proliferative actions. Further, estrogen and its receptors have a definite impact on the response of human breast cancer cell lines to leptin and adiponectin. More in-depth studies are needed to provide additional and precise links between the in vivo development of breast cancer and the balance of adiponectin and leptin.

show abstract

“…In primary breast cancer tissue sections, adiponectin was expressed in both normal epithelial and myoepithelial tissues [29] and was associated with increased breast cancer risk [28].…”

Section: Expression Of Adiponectin and Adipors In Breast Cancermentioning

confidence: 99%

Adiponectin and breast cancer

Chen¹,

Wang²

2010

Med Oncol

View full text Add to dashboard Cite

Adiponectin, an adipose tissue-derived hormone, has been studied intensively for the past decade because of its anti-inflammatory, anti-atherogenic, and anti-diabetic properties. Recent advances suggest that adiponectin also plays an important role in the development and progression of various cancers, especially obesity-related cancers. In this review, the authors focus on the potential role of adiponectin in breast cancer, an obesity- and endocrine-associated tumor. Epidemiological studies have shown that plasma adiponectin level is a risk factor for breast cancer in post-menopausal women. Adiponectin and its receptors are expressed on both breast cancer line cells and tumor tissues. Furthermore, exogenous adiponectin has exhibited therapeutic potential in animal models. Underlying mechanisms include the inhibition of cell proliferation and promotion of apoptosis, the regulation of tumorigenic-related factors, and the suppression of angiogenesis. The signaling pathways linking adiponectin with tumorigenesis might provide potential drug targets for the future. However, more convincing evidence is needed to fully elucidate the exact role of adiponectin in breast cancer, since both its beneficial effects and possible mechanisms remain controversial.

show abstract

Adiponectin and leptin expression in primary ductal breast cancer and in adjacent healthy epithelial and myoepithelial tissue

Cited by 42 publications

References 5 publications

Involvement of adiponectin and leptin in breast cancer: clinical and in vitro studies

Involvement of adiponectin and leptin in breast cancer: clinical and in vitro studies

Obesity and breast cancer: status of leptin and adiponectin in pathological processes

Adiponectin and breast cancer

Contact Info

Product

Resources

About